New York, January 16, 2026, 07:29 ET — Premarket
- Shares fell 24.5% in premarket trading following a 275% surge on Thursday
- The move comes after Attune Biotech signed a teaming agreement, forecasting $25-$45 million in potential revenue for Callan over the next five years
- Traders are watching for follow-on disclosures and if Thursday’s spike will persist into the open
Callan JMB Inc shares plunged 24.5% in premarket trading on Friday, following a steep, news-fueled surge the previous day.
Shares fell to $3.17 by 7:04 a.m. ET, slipping $1.03 from Thursday’s close of $4.20.
The pullback is significant since Thursday’s rally thrust this lightly capitalized stock back into the spotlight, with trading volume surging well beyond its usual pace. Now, the focus turns to whether the company can convert its headline-grabbing announcement into actual federal or commercial contracts.
Callan JMB ended Thursday up 275% from its previous close, with the stock bouncing between $2.54 and $5.61 during the day.
The spark came from a strategic teaming deal with Biostax Corp, operating as Attune Biotech. Callan JMB will serve as an independent overseer for manufacturing, quality systems, and deployment operations, the company announced.
Callan JMB projects combined revenue between $50 million and $75 million over the next five years. Under a profit-sharing deal ranging from 50% to 60%, Callan JMB’s cut is expected to be around $25 million to $45 million, depending on the contract’s scope.
The company positioned the deal around federal readiness efforts. Its Coldchain Technology Services unit has managed assets linked to agencies like BARDA — the Biomedical Advanced Research and Development Authority — and the Strategic National Stockpile, the government’s medical supply reserve.
Callan JMB’s Chief Executive Wayne Williams described the new teaming agreement as a step that broadens the company’s role within the federal medical countermeasure landscape. Attune CEO Noreen Griffin added that the deal “accelerates our path to federal deployment.” GlobeNewswire
Thursday’s session saw heavy action. Volume came in around 195.9 million shares, far above the three-month average of roughly 3.05 million, per .
There’s clear risk here. The revenue numbers are multi-year projections, and Attune remains clinical-stage — so the timeline and volume hinge on regulatory approvals plus whether federal or commercial buyers step up.
Callan JMB’s market cap was around $19.4 million, highlighting how sharply prices can swing when trading volume surges.
Traders will be watching to see if the stock steadies after its slide in premarket trading when the Nasdaq opens at 9:30 a.m. ET. They’ll also look for any new disclosures adding specifics on the contract’s timing, scope, or committed work tied to the Attune agreement.
